Sanofi and Janssen join forces to develop E.coli vaccine, with Sanofi's $175M upfront payment
Both companies will share the financial responsibility for ongoing and prospective research
Check out what's clicking on FoxBusiness.com
Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.
The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, on Sept. 30, 2023. (REUTERS/Gonzalo Fuentes/File Photo / Reuters Photos)
Under the terms of the deal, both parties will co-fund current and future research and development costs. Sanofi will pay $175 million upfront to Janssen, followed by development and commercial milestones.
CLICK HERE TO GET THE FOX NEWS APP
Load more..